Pre-made Zuberitamab benchmark antibody ( Whole mAb, anti-MS4A1/CD20 therapeutic antibody, Anti-B1/Bp35/CVID5/FMC7/LEU-16/S7 Antibody) for drug discovery and mechanism of action (MOA) research

Cat:GMP-Bios-ab-651

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

SKU GMP-Bios-ab-651 Category Tag

Product Details

Pre-Made Zuberitamab biosimilar, Whole mAb, Anti-MS4A1/CD20 Antibody: Anti-B1/Bp35/CVID5/FMC7/LEU-16/S7 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Zuberitamab is a biosimilar of rituximab [see Adis Insight Drug profile 800004275], a monoclonal antibody which targets CD20, being developed by Zhejiang Hisun Pharmaceutical, for the treatment of cancer, including diffuse large B-cell lymphoma.

Products Name (INN Index)

Pre-Made Zuberitamab biosimilar, Whole mAb, Anti-MS4A1/CD20 Antibody: Anti-B1/Bp35/CVID5/FMC7/LEU-16/S7 therapeutic antibody

INN Name

Zuberitamab

Target

MS4A1

Format

Whole mAb

Derivation

NA

Species Reactivity

Human

CH1 Isotype

IgG1

VD LC

Kappa

Highest_Clin_Trial (Jan '20)

Phase-II

Est. Status

Discontinued

100% SI Structure

None

99% SI Structure

None

95-98% SI Structure

3bky:HL

Year Proposed

2019

Companies

Zhejiang Hisun Pharmaceutical

Conditions Approved

NA

Conditions Active

NA

Conditions Discontinued

Diffuse large B-cell lymphoma

Development Tech

NA

Previous Name

NA

Gm Offical Target Name

MS4A1

Package

, ,

Genemeidi Omicron Variant Products
test
Previous slide
Next slide